Kelly Paul Edward 4
4 · RELMADA THERAPEUTICS, INC. · Filed May 20, 2025
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Purchase
Common Stock
2025-05-16$0.43/sh+200,000$86,060→ 412,295 total
Footnotes (2)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $0.4071 to $0.4498 per share, inclusive.